

LIFEFEST 2026

Nashville



Current and Emerging Research & Trials in Liposarcoma:
Cell Therapy & Exploring Potential in Sarcoma

Dr. Morganna Vance



Cell Therapy & Exploring Potential in Sarcoma

July 2026

ADVANCING IMMUNO-ONCOLOGY

Legal Disclaimer

Lifileucel is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. This indication is approved under accelerated approval based on objective response rate (ORR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

This presentation may contain information on an investigational agent(s) or investigational uses of approved agent(s) that has not been reviewed or approved by the US FDA or other regulatory authorities. Iovance does not endorse or recommend any unapproved use of its products. Please refer to product prescribing information, where available.

All statements contained herein should be taken in the context of providing educational updates on data from Iovance investigational trials to healthcare providers who are affiliated with institutions currently involved in Iovance-sponsored or collaborative research, are affiliated with institutions currently under CDA.

Cell Therapy: Turning the Immune System Against Cancer

Cell therapy is a form of immunotherapy that uses a patient's own immune cells — or cells from a donor — to recognize and attack cancer. Often called “living drugs,” these therapies have transformed cancer treatment over the past four decades.

Key Milestones




- ▶ **1980s–90s** Researchers discover immune cells inside tumors (TILs) can destroy cancer cells
- ▶ **2017** First chimeric antigen receptor (CAR) T-cell therapies approved for blood cancers
- ▶ **2024** FDA approves first TIL therapy for melanoma and first T cell receptor (TCR) therapy for a rare sarcoma
- ▶ **Today** Researchers are expanding cell therapies to multiple types of cancer, including sarcoma, lung cancer, gynecological cancers, and other solid tumors

What Is TIL Therapy?

TIL stands for **Tumor-Infiltrating Lymphocytes** — immune cells that are naturally found inside your tumor. These cells have already learned to recognize your cancer. TIL therapy is a **one-time treatment** that uses your body's own immune system to fight cancer.


How It Works

- ▶ A small piece of your tumor is surgically removed
- ▶ The immune cells inside it are extracted and grown into billions at a specialized lab
- ▶ After a short course of chemotherapy to prepare your body for the TIL therapy, the expanded cells are infused back into you through an IV



The goal: your boosted immune cells seek out and attack cancer cells throughout your body


The TIL Therapy Journey



Investigating TIL Cell Therapy in Sarcoma

A clinical trial will investigate TIL therapy in two sarcoma subtypes in patients with **undifferentiated pleomorphic sarcoma (UPS)** or **dedifferentiated liposarcoma (DDLPS)** who have received at least one prior line of systemic therapy

Clinical Trial Schema



For More Information: tilcelltherapy.com



Clinical Trials

TIL Cell Therapy Clinical Trials ▾

Investigational TIL Cell Therapy ▾

Investigational TIL Cell Therapy Clinical Trials



Thank You

ADVANCING IMMUNO-ONCOLOGY

LIFEFEST2026

Nashville



LIPOSARCOMA
SUPPORT  NETWORK

Thank you to our sponsors for supporting our mission
to present high-quality education, engagement & support
to the liposarcoma community!

